Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an AI coach and simple exercises help cancer patients fight frailty?

NCT ID NCT07732543

Symptom relief Sponsor: Taipei Veterans General Hospital, Taiwan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial tests whether a nurse-led program combining an AI chatbot and home-based exercises can help advanced gastric cancer patients on immunotherapy feel less frail and have a better quality of life. Participants use the chatbot to report side effects and get personalized advice, and follow a tailored exercise plan for 12 weeks. The study compares this group to those receiving usual care to see if the program reduces frailty, boosts self-confidence, and improves overall well-being.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI chatbot-guided symptom management education and home-based exercise program
What this could lead to
If effective, this approach could offer a practical, non-drug way to help advanced gastric cancer patients stay stronger and feel better during immunotherapy.
What could go wrong
This is a relatively small, early-stage trial. The intervention requires active participation, and results may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. age ≥18 years 2. diagnosed as AGC (TNM: T2\~T4, N\>0, Any M, Stage: III\~IV, or unresectable GC) 3. scheduled to receive the first cycle of immunotherapy 4. willingness to provide written informed consent after receiving a full explanation of the study Exclusion Criteria: 1. a diagnosis of another type of cancer within the past five years 2. inability to communicate clearly 3. a diagnosis of dementia 4. acute pulmonary embolism 5. acute myocardial infarction 6. extremity bone fracture within the past three months 7. bone metastasis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastric cancer (GC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastric cancer (GC) Immunotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.